Home visits reduce readmission in elderly patients

Having a home health worker can reduce rates of readmission for older patients, according to a study conducted by the Indiana University Center for Aging Research and Regenstrief Institute. Findings were presented in the Journal of the American Medical Directors Association.

To examine readmissions in elderly patients recovering at skilled nursing facilities (SNF), researchers evaluated readmission rates after visits by home health workers such as a nurse or physical therapist. The aim of the study was to showcase the importance of home health workers in the care continuum and outline the benefits.

"A hospital admission is a stressful event for an older adult, and when they go home, our duty is to ensure they have all the tools they need to successfully remain independent at home. We conducted this study of more than 1,500 community-dwelling older adults because patient characteristics and other factors that can help to prevent the older adult's return to the hospital are poorly understood," said IU Center for Aging Research and Regenstrief Institute investigator Jennifer Carnahan, MD, MPH, an IU School of Medicine assistant professor of medicine who led the study."

The study evaluated 1,500 elderly patients who had been discharged to a SNF and evaluated rates of readmission within 30 days. Results showed that home health visits within a week of discharge reduced rates of 30-day readmission while outpatient physician visits did not reduce readmission.

"We hope these findings will encourage policy makers to make home health care more widely available. An early home health visit may be a great way to improve the chances that the older adult won't need to come back to the hospital so soon," said study senior author, Alexia Torke, MD, associate director of the IU Center for Aging Research, Regenstrief Institute investigator and associate professor medicine at IU School of Medicine.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.